Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2025 Jan 25

PMID 39861758

Authors

Yahya H Dallal Bashi

Rachel Mairs

Rand Murtadha

Vicky Kett

Affiliations

Soon will be listed here.

Abstract

This paper presents a comprehensive review of the current literature, clinical trials, and products approved for the delivery of antibiotics to the lungs. While there are many literature reports describing potential delivery systems, few of these have translated into marketed products. Key challenges remaining are the high doses required and, for powder formulations, the ability of the inhaler and powder combination to deliver the dose to the correct portion of the respiratory tract for maximum effect. Side effects, safety concerns, and disappointing clinical trial results remain barriers to regulatory approval. In this review, we describe some possible approaches to address these issues and highlight prospects in this area.

References

Elborn J . Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6. View

Logan L, Weinstein R . The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis. 2017; 215(suppl_1):S28-S36. PMC: 5853342. DOI: 10.1093/infdis/jiw282. View

Mah T, OToole G . Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001; 9(1):34-9. DOI: 10.1016/s0966-842x(00)01913-2. View

Sithu Shein A, Wannigama D, Hurst C, Monk P, Amarasiri M, Badavath V . Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection. Biomed Pharmacother. 2024; 168:115793. DOI: 10.1016/j.biopha.2023.115793. View

Eikani M, Nugent M, Poursina A, Simpson P, Levy H . Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis. BMC Infect Dis. 2018; 18(1):311. PMC: 6035392. DOI: 10.1186/s12879-018-3200-z. View

Chang R, Chow M, Wang Y, Liu C, Hong Q, Morales S . The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice. Clin Microbiol Infect. 2022; 28(7):983-989. DOI: 10.1016/j.cmi.2022.01.006. View

Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A . Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 1991; 58(3-4):145-9. DOI: 10.1159/000195915. View

Alhajj N, Yahya M, OReilly N, Cathcart H . Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis. Eur J Pharm Sci. 2023; 192:106654. DOI: 10.1016/j.ejps.2023.106654. View

Pasteur M, Bilton D, Hill A . British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65(7):577. DOI: 10.1136/thx.2010.142778. View

10.

Pilcer G, Amighi K . Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010; 392(1-2):1-19. DOI: 10.1016/j.ijpharm.2010.03.017. View

11.

Muddle J, Kirton S, Parisini I, Muddle A, Murnane D, Ali J . Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks. J Pharm Sci. 2016; 106(1):313-321. DOI: 10.1016/j.xphs.2016.10.002. View

12.

Ali A, Zawbaa H, Sayed O, Harb H, Saeed H, Boshra M . In vitro and in vivo performance modelling and optimisation of different dry powder inhalers: A complementary study of neural networks, genetic algorithms and decision trees. Int J Clin Pract. 2020; 75(3):e13764. DOI: 10.1111/ijcp.13764. View

13.

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

14.

Ray W, Murray K, Hall K, Arbogast P, Stein C . Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012; 366(20):1881-90. PMC: 3374857. DOI: 10.1056/NEJMoa1003833. View

15.

Martiniano S, Wagner B, Levin A, Nick J, Sagel S, Daley C . Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. Chest. 2017; 152(4):800-809. DOI: 10.1016/j.chest.2017.04.175. View

16.

Sherrard L, Bell S, Tunney M . The role of anaerobic bacteria in the cystic fibrosis airway. Curr Opin Pulm Med. 2016; 22(6):637-43. DOI: 10.1097/MCP.0000000000000299. View

17.

Poole K . Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol. 2001; 3(2):255-64. View

18.

Fiel S, Roesch E . The use of tobramycin for Pseudomonas aeruginosa: a review. Expert Rev Respir Med. 2022; 16(5):503-509. DOI: 10.1080/17476348.2022.2057951. View

19.

Atlas N, Uzair B, Movellan J, Gracia R, Dupin D, Loinaz I . activity of novel apramycin-dextran nanoparticles and free apramycin against selected Dutch and Pakistani isolates. Heliyon. 2023; 9(12):e22821. PMC: 10730580. DOI: 10.1016/j.heliyon.2023.e22821. View

20.

Elborn J, Flume P, Van Devanter D, Procaccianti C . Management of chronic infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiol. 2021; 16:1087-1104. DOI: 10.2217/fmb-2021-0150. View